Quality statement 12: Systemic therapy for advanced non‑small‑cell lung cancer

Quality statement 12: Systemic therapy for advanced non‑small‑cell lung cancer

Quality statement

People with stage IIIB or IV non‑small‑cell lung cancer are offered systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

Quality measure

Structure: Evidence of local arrangements and written clinical protocols to ensure that people with stage IIIB or IV non‑small‑cell lung cancer are offered systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

Process:

Proportion of people with stage IIIB or IV non‑small‑cell lung cancer who receive systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

Numerator – the number of people in the denominator who receive systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

Denominator – the number of people with stage IIIB or IV non‑small‑cell lung cancer.

What the quality statement means for each audience

Service providers ensure there are systems in place for people with stage IIIB or IV non‑small‑cell lung cancer to be offered systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

Healthcare professionals offer systemic therapy to people with stage IIIB or IV non‑small‑cell lung cancer in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

Commissioners ensure they commission services for people with stage IIIB or IV non‑small‑cell lung cancer to be offered systemic therapy in accordance with NICE guidance, that is directed by histology, molecular markers and PD-L1 expression.

People with advanced (stage IIIB or IV) non‑small‑cell lung cancer are offered chemotherapy in accordance with NICE guidance, determined by the type of the tumour (histology) and other laboratory tests.

Source guidance

Data source

Structure: Local data collection.

Process:

a) The Health and Social Care Information Centre National Lung Cancer Data Audit collects data on the proportion of patients submitted to the audit receiving chemotherapy for stage IIIB and IV (performance status 0 and 1) non‑small‑cell lung cancer.

b) Local data collection.

Data fields necessary for the extraction of data on patients receiving cancer chemotherapy are available in the National Cancer Intelligence Network Systemic Anti-Cancer Therapy dataset.

Definitions

Systemic therapy includes conventional cytotoxic chemotherapy and biological agents that target specific molecular pathways on the tumour to inhibit cellular function.

People with stage IIIB or IV non‑small‑cell lung cancer are offered systemic therapy in accordance with the NICE guideline on lung cancer, recommendations 1.4.45–1.4.51.